Biogen (BIIB) reported first-quarter 2024 adjusted earnings per share (EPS) of $3.67, beating the Zacks Consensus Estimate of $3.45. Earnings rose 8% year over year, driven by savings in operating costs and margin improvements. On a constant-currency basis, earnings were flat.Total revenues came in at $2.29 billion, down 7% on both reported basis and constant-currency basis from the year-ago quarter due to lower sales of key multiple sclerosis (MS) drugs like Tecfidera and Tysabri as well as spinal muscular ...

Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Alisha Alaimo - Head and President of North-America Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald Paul Matteis - Stifel Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Michael Yee - Jefferies Colin Brist ...

For the quarter ended March 2024, Biogen Inc. (BIIB) reported revenue of $2.29 billion, down 7% over the same period last year. EPS came in at $3.67, compared to $3.40 in the year-ago quarter.The reported revenue represents a surprise of -1.09% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.45, the EPS surprise was +6.38%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their n ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million. However, the company demo ...

Press Release Cambridge, Mass. – Apr. 24, 2024 Biogen reports first quarter 2024 GAAP EPS growth of 1% and Non-GAAP EPS growth of 8% First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67 First quarter product revenue decreased 3% and total revenue decreased 7%, while GAAP operating income grew 10% and Non-GAAP operating income grew 24%; meaningful improvement in both gross and operating margins due to Fit for Growth program and R&D prioritization LEQEMBI launch uptake accele ...

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected.Biogen and Eisai's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. The treatment's launch has been sluggish, but uptake appeared ...

In the latest market close, Biogen Inc. (BIIB) reached $214.83, with a -0.37% movement compared to the previous day. This change lagged the S&P 500's 0.2% loss on the day. On the other hand, the Dow registered a loss of 0.6%, and the technology-centric Nasdaq increased by 0.11%.Heading into today, shares of the company had lost 2.41% over the past month, lagging the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.The investment community will be closely monitoring the performance ...

TOKYO and CAMBRIDGE, Mass., March 31, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatmen ...

Biogen Inc. (NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ET Company Participants Priya Singhal - Head of Development & Interim Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Operator Paul Matteis Great. Thank you. Good morning, everybody. It's my pleasure to be hosting this panel with Priya Singhal, Head of Development; and now also Interim Chief Medical Officer at Biogen. Priya has done this panel with me a couple of years in a row, and there's alw ...

Biogen Inc. (NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ET Company Participants Priya Singhal - Head of Development & Interim Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Operator Paul Matteis Great. Thank you. Good morning, everybody. It's my pleasure to be hosting this panel with Priya Singhal, Head of Development; and now also Interim Chief Medical Officer at Biogen. Priya has done this panel with me a couple of years in a row, and there's alw ...